AptaBio Therapeutics Inc. (293780.KQ)
KOSDAQ · KRW · Healthcare · Drug Manufacturers - Specialty & Generic
₩6,030 (+4.15%) as of
Key statistics
- Market cap
- 169.40B
- Dividend yield
- 0.00%
- 52-week range
- 3,870.00 – 10,890.00
- Beta
- 0.89
- Revenue (TTM)
- 4.75B
- Profit margin
- 0.00%
- Volume
- 62.15k
About AptaBio Therapeutics Inc.
AptaBio Therapeutics Inc., a biopharmaceutical company, develops platform based drugs for intractable diseases. Its platforms include Oxidative stress modulation platform for developing therapeutic agents for diabetes complications, vascular diseases, neurodegenerative diseases, and intractable cancers by controlling oxidative stress; Cancer-associated fibroblast control platform for developing new anticancer drugs for intractable cancer; and Aptamer-drug conjugate platform for developing intractable anticancer drugs with high unmet medical needs. The company offers Lipofector-Q, Lipofector-EXT, Lipofector-2000, Lipofector-EZ, and Lipofector-pMAX reagents for transfecting DNA or RNA into eukaryotic cells. The company was founded in 2009 and is based in Yongin-si, South Korea.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Yongin-si, South Korea
- Employees
- 44
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.